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tisol concentrations are higher in the epilepsy group than in 
the control group. After VNS, these concentrations de-
creased. The concentrations of the tryptophan metabolites 
were lower in the epilepsy group than in the control group. 
The KYNA ratios are defined as the ratio of neuroprotective 
KYNA versus neurotoxic 3-OH-KYN and KYNA versus neuro-
toxic kynurenine: these ratios were lower in epilepsy pa-
tients than in controls, and they both moderately increased 
after VNS.  Conclusion: The outcome of this preliminary 
study indicates that VNS causes a rebalancing of the immune 
system. This results in: (1) a reduction of neurotoxic and an 
increase of neuroprotective kynurenine metabolites and (2) 
in the normalization of cortisol levels. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Vagus nerve stimulation (VNS) is an alternative treat-
ment for intractable epilepsy. The mode of action is as-
sumed to be the result of modulation of deep brain struc-
tures by neuroactive substances. The severity of epileptic 
seizures is causally related to central inflammatory and 
neurotransmitter functions  [1–5] . 
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 Abstract 
 Objective: The vagus nerve has important immunological 
functions that may be relevant for its anticonvulsive action. 
We postulate that this anticonvulsive action is activated by a 
shift in the immune system resulting in a reduction of neu-
rotoxic and an increase of neuroprotective tryptophan me-
tabolites.  Methods: Eleven patients with refractory epilepsy 
and 11 controls matched for age and gender were included 
in this study. The primary outcome measure was a 50% sei-
zure reduction. Other variables were pro-inflammatory cy-
tokines IL-6 and TNF-  , anti-inflammatory cytokine IL-10, 
cortisol, and the tryptophan metabolites 3-hydroxykyn-
urenine (3-OH-KYN), kynurenic acid (KYNA), kynurenine, se-
rotonin (5-HT) and 5-hydroxyindol acetic acid (5-HIAA). 
Blood samples were scheduled during baseline, and in week 
28 of add-on treatment.  Results: IL-6 levels were higher in 
the responders than in the control group, and decreased af-
ter vagus nerve stimulation (VNS), whereas IL-10 was low and 
increased after VNS. In nonresponders, VNS resulted in an 
increase of IL-6 plasma levels and in a decrease of IL-10. Cor-
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 Tryptophan metabolites are involved in the stimula-
tion of glutaminergic N-methyl- D -aspartate (NMDA) 
receptors. Overstimulation of NMDA receptors has 
been implicated in the generation of seizures  [6, 7] . The 
vagus nerve has a major impact in attenuating inflam-
matory responses via the so-called anticholinergic reflex 
loop  [8] ( fig. 1 ). The pro-inflammatory cytokines influ-
ence the serotonin (5-HT) and kynurenine metabolism 
 [7–9] . VNS also results in changes of tryptophan me-
tabolite concentrations in the brain  [10, 11] ( fig. 2 ). How-
ever, the exact mechanism behind seizure frequency re-
duction and improvement of well-being in VNS is still 
unknown. 
 We postulate that the beneficial effect of VNS is acti-
vated by a shift in the immune system, resulting in a re-
duction of neurotoxic and an increase of neuroprotective 
tryptophan metabolites.
 In the presented pilot study we aimed at: (1) evaluat-
ing the effectiveness of VNS, (2) evaluating the effects of 
VNS on the immune system and changes in the trypto-
phan  metabolic pathway, and (3) linking the therapeutic 
effect of VNS to changes in the tryptophan metabolic 
pathway. 
 Subjects and Methods 
 We studied 11 patients with intractable epilepsy and 11 con-
trols matched for age and gender. Patients and controls with 
known immune compromising diseases, infectious diseases or 
pregnancy were excluded. No changes in medication were al-
lowed during the study. The study was approved by the medical 
ethics committee. 
 Seizure frequency per month at 6 months of VNS was com-
pared with seizure frequency per month at baseline. The primary 
endpoint was a seizure frequency reduction of 50% or more. The 
main variables were: demographics, epilepsy-specific data, and 
biochemical and neuro-immunological variables in peripheral 
blood. Blood sampling was scheduled during baseline and in week 
28 of add-on treatment. The time interval between the last seizure 
and blood sampling was 24 h or more.
 IL-6 and TNF-  (pro-inflammatory cytokines), IL-10 (an-
ti-inflammatory cytokine), 5-HT, kynurenine, kynurenic acid 
(KYNA), 3-hydroxykynurenine (3-OH-KYN), and 5-hydroxyin-
dol acetic acid (5-HIAA) were assessed. The ‘neuroprotective ra-
tio’ was determined to evaluate whether the effect of VNS is neu-
roprotective or neurotoxic. As we were unable to determine the 
concentration of quinolinic acid (neurotoxin), the KYNA/kyn-
urenine and KYNA/3-OH-KYN ratios were determined to assess 
the balance between the neuroprotective and neurotoxic arm of 
the kynurenine metabolism. EDTA blood was collected and cen-
trifuged. It was stored at –70  °  C until analysis was performed. For 
determination, 7 mm of plasma were used. 
 The cytokine assessments were performed with an ELISA 
technique (R&D Quantikine HS). In some samples, the cytokine 
concentrations were below the detection level. The level of detec-
tion of IL-6 was 0.4 pg/ml, 1 pg/ml for TNF-  and 1.5 pg/ml for 
IL-10. While results below the level of detection cannot be regard-
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 Fig. 1. The anticholinergic reflex loop. 
 Fig. 2. 5-HT = Serotonin; 3-OH-KYN = 3-hydroxykynurenine; 
KYNA = kynurenic acid; IDO = indoleamine (2,3)-dioxygenase; 
KH = kynurenine hydroxylase. 
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ed as missing, they cannot be regarded as true values. We there-
fore assumed IL-6 values  ! 0.4 pg/ml to be 0.2 pg/ml, TNF-  
 ! 1 pg/ml to be 0.5 pg/ml and IL-10  ! 1.5 pg/ml to be 0.75 pg/ml. 
 Tryptophan, 5-HT and kynurenine metabolites were assessed 
by use of HPLC.
 Non-parametric statistics were used to analyze the data. The 
Mann-Whitney test was used to compare the controls with the 
baseline group. The Wilcoxon test was used to compare the results 
at baseline with the results after 28 weeks of treatment. 
 Results 
 The control group consisted of 6 males and 5 females 
with ages ranging from 10–64 years (median age: 28). The 
epilepsy group also consisted of 6 males and 5 females. 
The ages in the epilepsy group ranged from 12–58 years 
(median age: 30).
 Six patients had cryptogenic localization-related epi-
lepsy, four had symptomatic epilepsy and one had gener-
alized epilepsy. The median duration of the epilepsy was 
19 years. The patients had used 5–15 drugs before. One 
patient had been operated on and one had been on a ke-
togenic diet.
 The reduction of the mean seizure frequency was 21%. 
The responder rate was 36%.
 VNS resulted in an increase of the IL-6 (pro-inflam-
matory) plasma levels and in a decrease in IL-10 (anti-
inflammatory) plasma levels, thus converging to the val-
ues of the control group. TNF-  concentrations were 
above the detection level in only 33% of the samples, 
which makes it difficult to interpret the results. For IL-10 
and IL-6, 76 and 64% of the measured concentrations 
were above the detection level. 
 Most of the responders had detectable cytokine levels. 
In this subgroup of responders, we measured a decrease 
in the pro-inflammatory cytokine IL-6 in all responders. 
An increase of anti-inflammatory cytokine IL-10 after 
VNS was seen in two out of four responders. The re-
sponders who already showed high levels of IL-10 (n = 2) 
did not show a further increase after VNS. None of the 
differences reached a level of statistical significance.
 Epilepsy patients had a higher cortisol concentration 
than controls (346 vs. 326 nmol/l). After VNS, the levels 
decreased (286 nmol/l). 
 In the subgroup of responders, three out of four pa-
tients showed a decrease of cortisol concentrations after 
VNS. The one patient whose cortisol level did not change 
after VNS already had a low cortisol level at baseline. 
 Most tryptophan metabolites were lower in epilepsy 
patients than in healthy individuals. After treatment, 
kynurenine and tryptophan decreased. We noticed an in-
crease in the serotonin metabolite 5-HIAA and kynuren-
ine metabolites KYNA and 3-OH-KYN. None of the dif-
ferences reached a level of statistical significance ( table 1 ). 
Only the KYNA assessment had missing values (2 sam-
ples at baseline and 3 samples after VNS).
 Epilepsy patients showed lower KYNA ratios than 
controls. These ratios moderately increased after VNS 
( table 1 ). Unfortunately, three of five missing values oc-
curred in the subgroup of responders (n = 4), leaving us 
with only one responder in whom we were able to assess 
the baseline and post-VNS KYNA/3-OH-KYN ratio. In 
 Table 1. Peripheral blood samples  
Control n Baseline n After n p1 p2
IL-6, pg/ml 0.68 (0.2–1.57) 8 0.50 (0.2–1.45) 7 0.61 (0.2–1.42) 6 0.75 0.37
TNF-, pg/ml 0.5 (0.5–1.89) 4 1.03 (0.5–2.39) 6 0.5 (0.5–2.56) 2 0.65 0.74
IL-10, pg/ml 1.68 (0.75–34.12) 7 2.45 (0.75–21.59) 8 2.13 (0.75–15.18) 10 0.9 0.15
Tryptophan, g/ml 11.3 (8–14.6) 11 10.8 (4.6–15.3) 11 9.8 (4.2–352.8) 11 0.52 0.66
5-HIAA, ng/ml 7.8 (2.7–41.5) 11 3.6 (2.6–9.5) 11 6.0 (2.3–7) 11 0.08 0.29
KYNA, ng/ml 6.6 (5.1–14.9) 11 4.8 (3.7–17.6) 9 6.4 (3.3–10) 8 0.24 0.75
3-OH-KYN, ng/ml 9.2 (7.5–11.2) 11 9.1 (6.3–12) 11 9.8 (8.2–12.4) 11 0.9 0.92
Kynurenine, ng/ml 503.5 (402.9–873.4) 11 399.5 (277–742.7) 11 317.4 (14.1–593) 11 0.07 0.18
KYNA/3-OH-KYN 0.72 (0.52–1.99) 11 0.64 (0.36–1.71) 9 0.65 (0.5–2.67) 8 0.4 0.92
KYNA1,000/kynurenine 13 (7.1–37) 11 12.8 (5.79–47.86) 9 16.1 (11.92–156.13) 8 0.9 0.46
 Values are medians (min.–max.). n = Number of samples.
1 Mann-Whitney test (control – baseline). 2 Wilcoxon (baseline – after VNS).
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this patient, the neuroprotective ratio was increased after 
VNS because the increase in KYNA was larger than the 
increase in 3-OH-KYN. 
 Discussion 
 A responder rate of 36% is in line with the results 
known from observational and controlled studies on 
VNS in epilepsy  [12, 13] .
 Based on the literature, one would expect a pro-in-
flammatory status in patients with epilepsy  [3, 14, 15] . 
Our preliminary data did not confirm the previous find-
ings. Again, based on the literature one would expect 
VNS to provoke an anti-inflammatory reaction  [3, 4, 16–
19] . Our preliminary data did not confirm this observa-
tion either. An increased pro-inflammatory reaction af-
ter VNS was also described by Corcoran et al.  [20] , who 
studied cytokine reactions in 10 patients with therapy-
resistant depression. Nevertheless, marked increases in 
pro-inflammatory cytokines are presumably non-thera-
peutic. Our findings are in line with our expectations 
only if we analyze the responders as a subgroup: most re-
sponders showed a pro-inflammatory status before VNS 
treatment and an anti-inflammatory reaction after VNS. 
Those responders who already had high anti-inflamma-
tory IL-10 levels at baseline did not show a further in-
crease after VNS.
 The decrease of 5-HIAA concentration in intractable 
epilepsy patients that we observed can be explained by 
the following hypothesis, which is also explained in  fig-
ure 2 . According to this neurodegeneration hypothesis, 
increased levels of pro-inflammatory cytokines influ-
ence the tryptophan metabolism, resulting in decreased 
metabolism of tryptophan to 5-HT and increased me-
tabolism of tryptophan to kynurenine. This subsequent-
ly leads to an imbalance between the neuroprotective 
NMDA receptor antagonist KYNA and the neurotoxic 
3-OH-KYN  [7–9] . The reduced KYNA/kynurenine and 
KYNA/3-OH-KYN ratios in epilepsy patients are in line 
with this neurodegeneration hypothesis. These results 
are indicative of an imbalance between neuroprotective 
and neurotoxic metabolites in epilepsy patients, and with 
previous reports showing significantly lower levels of 
neuroprotective KYNA in children with intractable epi-
lepsy than in healthy controls  [21–23] . 
 Hypothalamic pituitary adrenal axis dysfunction or a 
state of hypercortisolemia can be correlated with cogni-
tive deficits specific to medial temporal lobe memory, de-
pression and epilepsy  [24, 25] . The high cortisol levels at 
baseline and the decrease after VNS are in line with these 
studies and with our anti-inflammatory concept.
 The purpose of this preliminary study was to deter-
mine which parameters were of value in assessing the an-
ti-inflammatory action of VNS as a possible explanation 
of its therapeutic action. The interpretation of our results 
is only tentative due to the small number of patients, the 
rapid changes in cytokine concentrations, and the in-
volvement of several central and peripheral networks. 
However, it appears that epilepsy patients who respond to 
VNS show a trend towards rebalancing the immune sys-
tem as well as the 5-HT and kynurenine metabolism.
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